Storm Anesthesia Insight: Peptide Therapy for Pain: Promising but Murky
Mar 4
/
Michael Storm, DNAP, CRNA
Storm Anesthesia Insights - High-yield anesthesia updates for SRNAs preparing for the NCE, SEE, and clinical practice.
This week: marijuana rescheduling implications for preop screening, peptide therapy's regulatory maze, and a viral floor code that exposed critical staffing failures.
In This Issue
This week: marijuana rescheduling implications for preop screening, peptide therapy's regulatory maze, and a viral floor code that exposed critical staffing failures.
In This Issue
- Marijuana moves to Schedule III: what it means for your patients
- BPC-157 peptides: navigating the murky regulatory landscape
- Floor code gone wrong: lessons from a dangerously understaffed unit
- AI glasses at the bedside: HIPAA nightmare or clinical tool?
- Switch to 'textbook brain' mode for NCE success
- Start your free SRNA board review trial
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|